Healthcare Services

Uveal Neoplasms Market Outlook 2026–2030 Exploring New Business Opportunities

April 7, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Uveal Neoplasms Market From 2026 To 2030?

The uveal neoplasms market has shown strong expansion over recent years. It is projected to expand from $1.14 billion in 2025 to $1.2 billion in 2026, registering a compound annual growth rate (CAGR) of 5.7%. The market’s growth in the past can be ascribed to enhanced ophthalmic diagnostic tools, the proliferation of specialized eye care centers, greater public awareness of ocular tumors, the accessibility of radiation-based therapies, and an increase in ophthalmic oncology expertise.

The uveal neoplasms market size is anticipated to experience significant expansion in the coming years. It will grow to $1.5 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. This projected growth over the forecast period is attributable to factors such as the increasing uptake of precision medicine in ophthalmology, rising investment in ocular oncology research, the expansion of immunotherapy applications, a growing demand for minimally invasive eye treatments, and the increasing use of advanced imaging diagnostics. Key developments expected during this period include a greater adoption of targeted and immunotherapy treatments, the rising use of advanced ocular imaging technologies, an amplified focus on early tumor detection, the expansion of personalized treatment regimens, and enhanced integration of multidisciplinary eye care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21312&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Uveal Neoplasms Market?

The increasing occurrence of eye cancer is projected to drive the expansion of the uveal neoplasms market going forward. Eye cancer refers to the uncontrolled proliferation of abnormal cells within the eye, which can manifest in various structures such as the retina, iris, or optic nerve. This upward trend in eye cancer cases can be attributed to factors including enhanced detection methods, environmental exposures, and an aging demographic. Uveal neoplasms, particularly uveal melanoma, are a rare form of ocular malignancy that possess the capability to metastasize to other organs, notably the liver, thereby posing significant health risks. For instance, in 2023, according to Cancer Research UK, a UK-based cancer research organization, eye cancer incidence rates in the UK are anticipated to rise by 50% between the 2023-2025 and 2038-2040 periods, ultimately reaching an average of 3 cases per 100,000 people each year by 2038. Consequently, the growing number of eye cancer diagnoses is fueling the growth of the uveal neoplasms market.

Which Segments Are Included In The Analysis Of The Uveal Neoplasms Market?

The uveal neoplasms market covered in this report is segmented –

1) By Treatment Type: Drugs, Therapy

2) By Route Of Administration: Oral, Injectable, Other Route Administration

3) By Distribution Channel: Hospitals Pharmacies, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Drugs: Chemotherapeutic Agents, Targeted Therapy Drugs, Immunotherapy Drugs

2) By Therapy: Radiation Therapy, Laser Therapy, Photodynamic Therapy

What Trends Are Advancing Progress In The Uveal Neoplasms Market?

Leading companies within the uveal neoplasms market are focusing on integrating advanced liver-directed treatment methods, such as percutaneous hepatic perfusion (PHP), to improve localized tumor control and lessen systemic toxicity. Percutaneous hepatic perfusion (PHP) is a minimally invasive procedure that isolates the liver’s blood supply to deliver high-dose chemotherapy directly into the hepatic artery, while simultaneously filtering the blood as it exits the liver, allowing for concentrated treatment at the tumor site with reduced exposure to the rest of the body. For instance, in August 2023, Delcath Systems, Inc., a US-based interventional oncology company, received U.S. Food and Drug Administration (FDA) approval for HEPZATO KIT, a PHP-based therapy designed for treating metastatic uveal melanoma with unresectable liver-dominant metastases, which involves targeted melphalan infusion and extracorporeal filtration of hepatic blood, with treatment cycles typically repeated every 6–8 weeks as clinically appropriate. The HEPZATO KIT facilitates a higher local drug concentration with diminished systemic exposure and has demonstrated clinically meaningful benefits, including tumor response and disease control in eligible metastatic uveal melanoma patients.

Which Key Industry Participants Are Active In The Uveal Neoplasms Market?

Major companies operating in the uveal neoplasms market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., IDEAYA Biosciences Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Verastem Oncology Inc., Iovance Biotherapeutics Inc., Immunocore Holdings PLC, Aura Biosciences, Foghorn Therapeutics Inc., Syncona Limited, iOnctura SA, Linnaeus Therapeutics, Inc., Delcath Systems Inc, Bellicum Pharmaceuticals Inc.

Read the full uveal neoplasms market report here:

https://www.thebusinessresearchcompany.com/report/uveal-neoplasms-global-market-report

What Are The Leading Geographic Regions In The Uveal Neoplasms Market?

North America was the largest region in the uveal neoplasms market in 2025. The regions covered in the uveal neoplasms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Uveal Neoplasms Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21312&type=smp

Browse Through More Reports Similar to the Global Uveal Neoplasms Market 2026, By The Business Research Company

Transdermal Skin Patche Global Market Report

https://www.thebusinessresearchcompany.com/report/transdermal-skin-patche-global-market-report

Retinitis Pigmentosa Global Market Report

https://www.thebusinessresearchcompany.com/report/retinitis-pigmentosa-global-market-report

Skin Cancer Diagnostics Global Market Report

https://www.thebusinessresearchcompany.com/report/skin-cancer-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795